Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?

Table 5

Overall survival and disease-specific survival by stage M according to the AJCC criteria and therapeutic modality, adapted from Culp et al. (2014) [13].

AJCC M-stage/therapeutic modality	5-year OS rate (%)	DSS rate (%)
		1 year	3 years	5 years
M1a
NLT	35,1	93,4	73,3	61,4
RP	64,3	98,4	92,9	89,1
BT	54,7	96,3	84,1	76,2
M1b
NLT	22,9	84,1	59,6	48,4
RP	70,1	94,1	83,4	77,6
BT	55,0	89,2	71,0	61,9
M1c
NLT	18,6	75,6	50,4	43,0
RP	60,7	91,1	80,0	75,6
BT	53,4	85,4	68,3	62,1

AJCC: American Joint Committee on Cancer; OS: overall survival; DSS: disease-specific survival; RP: radical prostatectomy; BT: brachytherapy; NLT: no local treatment.